Skip to content
OpenCapital
Get started

Arcturus Therapeutics ARCT Q4 2024 Annual earnings

Reported March 6, 2025 · After market close

Revenue$21.0MMiss by $23.6M
EPS-$1.11Miss by $0.78
Revenue estimate$44.6M
EPS estimate-$0.33

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$3.1M
EPS estimate-$1.07

Versus estimates

Revenue

Q1 2026$2.1MMiss by $4.2MQ4 2025$7.2MMiss by $8.7MQ3 2025$17.2MBeat by $1.1MQ2 2025$24.5MBeat by $6.2MQ1 2025$29.4MBeat by $6.0M
Q4 2024$21.0MMiss by $23.6M

Diluted EPS

Q1 2026-$0.95Beat by $0.06Q4 2025-$1.03Miss by $0.11Q3 2025-$0.49Beat by $0.31Q2 2025-$0.34Beat by $0.77Q1 2025-$0.52Beat by $1.06
Q4 2024-$1.11Miss by $0.78

Ask the moment Arcturus Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Arcturus Therapeutics report Q4 2024 earnings?
Arcturus Therapeutics (ARCT) reported Q4 2024 earnings on March 6, 2025 after market close.
What were Arcturus Therapeutics's Q4 2024 revenue and EPS?
Arcturus Therapeutics reported revenue of $21.0M and eps of $-1.11 for Q4 2024.
Did Arcturus Therapeutics beat estimates in Q4 2024?
Revenue missed the consensus estimate of $44.6M by $23.6M. EPS missed the consensus estimate of $-0.33 by $0.78.
Where can I find Arcturus Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-034787) directly on SEC EDGAR. The filing index links above go to sec.gov.